Clinical Trial Update: Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating pioglitazone for fatty liver disease in patients with HIV and hepatitis C was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Liver Disease
• HIV Infection
• Hepatitis C

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV, Hepatitis C | Phase 4 | Status: TERMINATED | Results posted: 2014-06-16